Dianthus (DNTH) CEO Garcia Marino Exercises Options, Sells Shares

What Happened

• Garcia Marino, CEO, President and a director of Dianthus Therapeutics (DNTH), exercised a total of 166,000 option shares (40,000 + 126,000) at $8.44 per share (total exercise cost $1,401,040) on August 7, 2026. On the same date he sold 166,000 common shares in multiple open-market transactions, generating aggregate proceeds of $17,945,450. Net cash (proceeds minus exercise cost) was approximately $16,544,410. These sales were disclosed as open-market dispositions.

Key Details

• Transaction date: August 7, 2026 (report filed same day).
• Options exercised: 166,000 shares at $8.44 ($337,600 for 40,000; $1,063,440 for 126,000).
• Shares sold: 166,000 shares in multiple blocks; weighted average sale prices and ranges reported (see filing footnotes). Aggregate sale proceeds: $17,945,450.
• Net proceeds after exercise cost: ~ $16.54M.
• Post-transaction holdings: the filing excerpt provided does not specify remaining shares owned after these transactions.
• Notable footnotes: F1 — sales effected under a Rule 10b5-1 trading plan adopted May 8, 2026. F2–F7 — weighted-average prices reported; each sale block covered multiple trades at specified price ranges. F8 — underlying option award vesting schedule (25% vested Nov 1, 2022; remainder vesting monthly over three years).
• Filing timeliness: filed on the same date as the transactions (timely, not late).

Context

• Practically, this looks like an exercise of vested options followed by immediate sale of the resulting shares (i.e., effectively a cashless outcome), since the number of shares exercised equals the number sold. Sales under a pre-established 10b5-1 plan are routine mechanisms executives use to diversify or monetize holdings and are not, by themselves, an indication of the insider’s view of the company’s prospects.